Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma

Conditions:   Stage III Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IV Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8
Interventions:   Drug: Olaparib;   Drug: Temozolomide
Sponsor:   National Cancer Institute (NCI)
Recruiting
Pub Date: 
Tuesday, March 19, 2019 - 9:00am